SASKATOON, Saskatchewan, Nov. 28, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV: PCRX) today announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer.
Mr. Dale has served as PharmaCorp's Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. "Paul's appointment reinforces the continuity of our operating model and our confidence in his leadership," said Alan Simpson, Executive Chairman of PharmaCorp. "His experience managing complex retail organizations and his steady execution throughout our acquisition and integration efforts make him exceptionally well-suited for this expanded mandate."
Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. "Calvin has played an important role in PharmaCorp's early development and in solidifying our relationship with PharmaChoice Canada," added Mr. Simpson. "We are pleased he will continue supporting PharmaCorp in an advisory capacity."
PharmaCorp is also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp's business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.
About PharmaCorp Rx Inc.
PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support, and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner. PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and will continue to acquire both PharmaChoice Canada bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX.
PharmaCorp actively welcomes discussions with pharmacy owners considering succession or sale. For more information about our acquisition program and process, please visit www.PharmaCorpRx.ca or contact our team confidentially. We are committed to seamless transitions that protect your legacy and serve your community.
For further information, please contact:
Investor Relations
info@pharmacorprx.ca
Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the anticipated responsibilities and contributions of Mr. Dale, Mr. LeRoux, and Ms. Sigler; the expected impact of the leadership changes on Corporation's operations, strategy, and growth; and the Corporation's goal to continue to acquire pharmacies as they come to market and to operate such pharmacies under the PharmaChoice Canada banner. This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes; and the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation and the ability of the Corporation to acquire such pharmacies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
